Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT116 + ALK inhibitor + RET inhibitor
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Small Molecules, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Oral
01
Overview
BNT116 + ALK inhibitor + RET inhibitor is a combination therapy regimen developed by BioNTech SE for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). The regimen centers on BNT116, an intravenously administered, unmodified mRNA-based lipoplex cancer vaccine that encodes six tumor-associated antigens frequently expressed in NSCLC: CLDN6, KK-LC-1, MAGE-A3, MAGE-A4, MAGE-C1, and PRAME. In the LuCa-MERIT-1 Phase I trial (NCT05142189), BNT116 is being evaluated in combination with oral small-molecule tyrosine kinase inhibitors (TKIs) targeting either anaplastic lymphoma kinase (ALK) or rearranged during transfection (RET) in patients whose tumors harbor these specific genetic rearrangements. The vaccine is designed to stimulate a robust T-cell response against cancer cells, potentially enhancing the clinical benefit of targeted TKI therapy.
- Other names
- BNT116 in combination with ALK or RET inhibitorsBNT-116 in combination with ALK or RET inhibitorsBNT 116 in combination with ALK or RET inhibitors
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)CT83 (Kita-Kyushu lung cancer antigen 1)PRAME (Preferentially expressed antigen in melanoma)CLDN6 (Claudin-6)MAGEA4 (Melanoma-associated antigen A4)MAGEA3 (Melanoma-associated antigen 3)RET (Rearranged during transfection receptor tyrosine kinase)MAGEC1 (Melanoma antigen family C1)
Beyond the preview
Go deeper on BNT116 + ALK inhibitor + RET inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT116 + ALK inhibitor + RET inhibitor.